Ibruxen (Ibrutinib) 140mg ^

Key Information

• Active Ingredient: Ibrutinib INN 140 mg.
• Manufacturer: Everest Pharmaceuticals Ltd..
• Therapeutic Class: Kinase inhibitor, specifically a Bruton's tyrosine kinase (BTK) inhibitor, which works by blocking signals that cancer cells need to grow and survive.
• Indications: Ibruxen is a prescription drug primarily indicated for the treatment of adult patients with:
  • Mantle cell lymphoma (MCL) who have received at least one prior therapy.
  • Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL), including those with a 17p deletion.
  • Waldenström macroglobulinemia (WM).
  • Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
  • Chronic graft versus host disease (cGVHD) in adults and children one year and older after failure of one or more lines of systemic therapy.

Important Considerations

• Dosage: The recommended dose varies by condition and can be 420 mg or 560 mg orally once daily. Capsules should be swallowed whole with water and not opened, broken, or chewed.
• Side Effects: Common side effects include diarrhea, fatigue, muscle and joint pain, rash, and bruising. Serious side effects can include severe bleeding, infections, heart problems, and high blood pressure.
• Drug Interactions: Avoid grapefruit and Seville oranges, as they can increase the amount of ibrutinib in the blood. Inform your doctor of any blood thinners or other medications you are taking, as interactions are possible.
• Availability: The medication is available from various online and local pharmacies, usually by prescription only.

Disclaimer: This information is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional for diagnosis and treatment of a medical condition.